Tesamorelin

Molecular Specifications

Tesamorelin (brand name Egrifta) is a synthetic GHRH analog consisting of the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid conjugate at the N-terminus. This modification provides resistance to DPP-IV cleavage at the critical Ala2 position — the primary site of native GHRH degradation — while maintaining full GHRH receptor binding activity. Tesamorelin carries the most extensive human pharmacological dataset of any research GHRH peptide, courtesy of its FDA-approved pharmaceutical indication.

GHRH Receptor Mechanism

Tesamorelin activates GHRH-R — a Gs-coupled GPCR on pituitary somatotrophs. Activation increases intracellular cAMP via adenylyl cyclase stimulation, activating PKA-dependent signaling that promotes GH gene transcription, GH synthesis, and pulsatile GH release. GH in turn stimulates hepatic IGF-1 production, completing the GH-IGF-1 axis.

Clinical Reference Data

Phase 3 trials for HIV-associated lipodystrophy documented: statistically significant reduction in trunk visceral adipose tissue (VAT) area, increased IGF-1 levels confirming GH axis activation, and effects on fasting glucose and insulin sensitivity markers — all providing quantitative reference parameters for preclinical model calibration.

↗ Falutz J et al. (2010). Effects of tesamorelin on visceral adiposity and liver fat in HIV-infected patients. AIDS. PubMed: 20400886

Research Applications

• GHRH receptor activation and GH axis pathway studies
• Pituitary somatotroph function research
• GH-IGF-1 axis kinetics in preclinical models
• Visceral adipose tissue biology and lipid metabolism research
• Comparison studies vs. shorter GHRH analogs (CJC-1295, sermorelin)